<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719664</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-3BNC117_201</org_study_id>
    <nct_id>NCT03719664</nct_id>
  </id_info>
  <brief_title>Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects</brief_title>
  <acronym>ABL</acronym>
  <official_title>A Phase 2, Multicenter, Three-part Study to Establish the Dosage, Safety and Antiviral Activity of Combination Therapy With Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects With HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frontier Biotechnologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Frontier Biotechnologies Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an adaptive, phase 2, multicenter, three-part study to establish the dosage,&#xD;
      safety and antiviral activity of combination therapy with albuvirtide (ABT) and 3BNC117 as&#xD;
      long-acting maintenance therapy in virologically suppressed subjects with HIV-1 infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a three-part, multicenter study that will enroll a total of 80 eligible, HIV-1&#xD;
      subjects who are virologically suppressed and stable on daily oral combination antiretroviral&#xD;
      therapy. The study will be conducted in three parts.&#xD;
&#xD;
      Part 1 and Part 2 are the dose-ranging portions of the study. In Part 1, 30 eligible subjects&#xD;
      will be randomized in a 1:1:1 ratio to receive 16 weeks of combination treatment with&#xD;
      albuvirtide and 3BNC117 or continue on the existing ART regimen under one of the three&#xD;
      cohorts as follows:&#xD;
&#xD;
        -  Cohort 1: albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks&#xD;
&#xD;
        -  Cohort 2: albuvirtide 0.32 g and 3BNC117 2 g every 4 weeks&#xD;
&#xD;
        -  Control Arm 1: Subjects continuing on baseline ART&#xD;
&#xD;
      In Part 2 of the study, 20 eligible subjects will be randomized in a 1:1 ratio to receive 16&#xD;
      weeks of combination treatment with albuvirtide and 3BNC117 under one of the two cohorts as&#xD;
      follows:&#xD;
&#xD;
        -  Cohort 3: albuvirtide 0.32 g and 3BNC117 0.8 g every 4 weeks&#xD;
&#xD;
        -  Cohort 4: albuvirtide 0.16 g and 3BNC117 0.8 g every 4 weeks&#xD;
&#xD;
      Part 3 of this study will enroll an additional 30 subjects in a 2:1 ratio to receive up to 28&#xD;
      weeks of combination treatment with optimal dose of albuvirtide and 3BNC117 or continue on&#xD;
      the existing ART regimen as follows:&#xD;
&#xD;
        -  Optimal Dose: albuvirtide and 3BNC11 every 2 or 4 weeks&#xD;
&#xD;
        -  Control Arm 2: Subjects continuing on baseline ART All consenting patients, in Cohort 1&#xD;
           and 2 (Part 1) and Cohort 3 and 4 (Part 2) of the study, will be shifted from daily oral&#xD;
           combination antiretroviral regimen to an intravenous infusion of ABT and 3BNC117. The&#xD;
           total treatmentduration with the ABT and 3BNC117 combination regimen will be up to 16&#xD;
           weeks (for Part 1 and Part 2) or 28 weeks (for Part 3) with a two week overlap of the&#xD;
           baseline oral antiretroviral regimen and the ABT-3BNC117 combination regimen at the&#xD;
           beginning of the study treatment and at the end of the treatment phase in subjects who&#xD;
           do not experience virologic rebound. During the two week overlap of baseline oral&#xD;
           antiretrovirals and ABT-3BNC117 combination regimen at the beginning of the study&#xD;
           treatment, subject will receive weekly doses of ABT and 3BNC117 as intravenous&#xD;
           infusions. Beyond the overlap period, subjects in Cohort 1 will receive study treatments&#xD;
           every two weeks and subjects in Cohort 2, 3, and 4 will receive study treatments every&#xD;
           four weeks.&#xD;
&#xD;
      Study participants will be monitored for viral rebound every two weeks following initiation&#xD;
      of ABT-3BNC117 combination and will re-initiate an oral antiretroviral regimen if virologic&#xD;
      rebound is confirmed with plasma HIV-1 RNA levels above 200 copies/ml on two consecutive&#xD;
      blood draws.&#xD;
&#xD;
      Pharmacokinetics of ABT and 3BNC117 will be assessed in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with HIV-1 RNA &lt; 50 copies/mL at the end of treatment phase in Part 3 of the study.</measure>
    <time_frame>28 weeks in Part 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HIV-1 RNA &lt; 50 copies/mL at the end of treatment phase in Part 1 of the study</measure>
    <time_frame>16 weeks in Part 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HIV-1 RNA &lt; 50 copies/mL at the end of treatment phase in Part 2 of the study</measure>
    <time_frame>16 weeks in Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to virologic rebound after discontinuation of baseline ART regimen</measure>
    <time_frame>16 weeks in Part 1 and part 2, 28 weeks in part 3</time_frame>
    <description>Note: Virologic rebound is defined as two consecutive HIV-1 RNA levels of &gt; 200 copies/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving HIV-1 RNA &lt; 50 copies/mL after experiencing virologic rebound</measure>
    <time_frame>16 weeks in Part 1 and part 2, 28 weeks in part 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieving HIV-1 RNA &lt; 50 copies/mL after experiencing virologic rebound</measure>
    <time_frame>16 weeks in Part 1 and part 2, 28 weeks in part 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in HIV-1 RNA, at each visit within the treatment phase</measure>
    <time_frame>16 weeks in Part 1 and part 2, 28 weeks in part 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in CD4 cell count, at each visit within the treatment phase</measure>
    <time_frame>16 weeks in Part 1 and part 2, 28 weeks in part 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in CD4:CD8 ratio, at each visit within the treatment phase</measure>
    <time_frame>16 weeks in Part 1 and part 2, 28 weeks in part 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergence of new resistance mutations to antiretroviral drugs as evaluated by GenoSure Archive or PhenoSense GT Assay</measure>
    <time_frame>16 weeks in Part 1 and part 2, 28 weeks in part 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of treatment adherence to the ABT and 3BNC117 combination regimen</measure>
    <time_frame>16 weeks in Part 1 and part 2, 28 weeks in part 3</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Cohort 1: albuvirtide &amp; 3BNC117</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: albuvirtide &amp; 3BNC117</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>albuvirtide 0.32 g and 3BNC117 2 g every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm 1: Baseline ART</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects continuing on baseline ART</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: albuvirtide &amp; 3BNC117</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>albuvirtide 0.32 g and 3BNC117 0.8 g every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: albuvirtide &amp; 3BNC117</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>albuvirtide 0.16 g and 3BNC117 0.8 g every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Dose: albuvirtide &amp; 3BNC117</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>albuvirtide and 3BNC117 every 2 or 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm 2: Baseline ART</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects continuing on baseline ART</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuvirtide</intervention_name>
    <description>Intravenous infusion of Albuvirtide</description>
    <arm_group_label>Cohort 1: albuvirtide &amp; 3BNC117</arm_group_label>
    <arm_group_label>Cohort 2: albuvirtide &amp; 3BNC117</arm_group_label>
    <arm_group_label>Cohort 3: albuvirtide &amp; 3BNC117</arm_group_label>
    <arm_group_label>Cohort 4: albuvirtide &amp; 3BNC117</arm_group_label>
    <arm_group_label>Optimal Dose: albuvirtide &amp; 3BNC117</arm_group_label>
    <other_name>Fusion inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3BNC117</intervention_name>
    <description>Intravenous infusion of 3BNC117</description>
    <arm_group_label>Cohort 1: albuvirtide &amp; 3BNC117</arm_group_label>
    <arm_group_label>Cohort 2: albuvirtide &amp; 3BNC117</arm_group_label>
    <arm_group_label>Cohort 3: albuvirtide &amp; 3BNC117</arm_group_label>
    <arm_group_label>Cohort 4: albuvirtide &amp; 3BNC117</arm_group_label>
    <arm_group_label>Optimal Dose: albuvirtide &amp; 3BNC117</arm_group_label>
    <other_name>Monoclonal antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baseline ART</intervention_name>
    <description>Subjects continuing on baseline ART</description>
    <arm_group_label>Control Arm 1: Baseline ART</arm_group_label>
    <arm_group_label>Control Arm 2: Baseline ART</arm_group_label>
    <other_name>ART</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Potential subjects are required to meet all of the following criteria for enrollment&#xD;
             into the study.&#xD;
&#xD;
               1. HIV-1 seropositive;&#xD;
&#xD;
               2. Males and females, age ≥18 years;&#xD;
&#xD;
               3. Receiving oral combination antiretroviral therapy for last 24 weeks;&#xD;
&#xD;
               4. No change in antiretroviral regimen within last 4 weeks prior to Screening Visit&#xD;
                  and in-between Screening Visit and First Treatment Visit with an exception that&#xD;
                  subjects on NNRTI-containing regimens will be allowed to switch to protease&#xD;
                  inhibitor- or integrase strand transferase inhibitor-based regimens and such&#xD;
                  change, if needed, should occur at least 4 weeks prior to cessation of oral&#xD;
                  antiretroviral therapy;&#xD;
&#xD;
               5. Subject has two or more potential alternative antiretroviral drug options&#xD;
                  available;&#xD;
&#xD;
               6. Plasma HIV-1 RNA &lt;50 copies/mL at Screening Visit as determined by Human&#xD;
                  Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Taqman® Real-Time PCR);&#xD;
&#xD;
               7. No documented detectable viral loads (HIV-1 RNA &gt; 50 copies/mL) within the last&#xD;
                  24 weeks prior to Screening Visit. An exception for a recorded HIV-1 RNA &quot;blip&quot;&#xD;
                  (e.g., transient HIV-1 RNA &lt;400 copies/mL) can be considered, although the&#xD;
                  preceding and following HIV-1 RNA measurements should be &lt;50 copies/mL;&#xD;
&#xD;
               8. CD4 cell count of &gt;300 cells/mm3 at Screening Visit;&#xD;
&#xD;
               9. Laboratory values at Screening:&#xD;
&#xD;
                    1. Absolute neutrophil count (ANC) ≥750/ mm3;&#xD;
&#xD;
                    2. Hemoglobin (Hb) ≥10.5 gm/dL (male) or ≥9.5 gm/dL (female);&#xD;
&#xD;
                    3. Platelets ≥75,000 /mm3;&#xD;
&#xD;
                    4. Serum alanine transaminase (SGPT/ALT) &lt;1.25 x upper limit of normal (ULN);&#xD;
&#xD;
                    5. Serum aspartate transaminase (SGOT/AST) &lt;1.25 x ULN;&#xD;
&#xD;
                    6. Serum total bilirubin within normal range; and&#xD;
&#xD;
                    7. Creatinine ≤1.5 x ULN.&#xD;
&#xD;
              10. Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal,&#xD;
                  considered not clinically significant by the Principal Investigator;&#xD;
&#xD;
              11. Both male and female subjects and their partners of childbearing potential must&#xD;
                  agree to use 2 medically accepted methods of contraception (e.g., barrier&#xD;
                  contraceptives [male condom, female condom, or diaphragm with a spermicidal gel],&#xD;
                  hormonal contraceptives [implants, injectables, combination oral contraceptives,&#xD;
                  transdermal patches, or contraceptive rings], and intrauterine devices) during&#xD;
                  the course of the study (excluding women who are not of childbearing potential&#xD;
                  and men who have been sterilized or who do not have sex with women). Females of&#xD;
                  childbearing potential must have a negative serum pregnancy test at Screening&#xD;
                  visit and negative urine pregnancy test prior to receiving the first dose of&#xD;
                  study drug;&#xD;
&#xD;
              12. Willing and able to participate in all aspects of the study, including use of&#xD;
                  intravenous medication, completion of subjective evaluations, attendance at&#xD;
                  scheduled clinic visits, and compliance with all protocol requirements as&#xD;
                  evidenced by providing written informed consent.&#xD;
&#xD;
        Note: Subjects diagnosed with either substance dependence or substance abuse or any history&#xD;
        of a concomitant condition (e.g., medical, psychologic, or psychiatric) may be enrolled if&#xD;
        in the opinion of site investigator these circumstances would not interfere with the&#xD;
        subject's successful completion of the study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Potential subjects meeting any of the following criteria will be excluded from&#xD;
             enrollment.&#xD;
&#xD;
               1. Any active infection or malignancy requiring acute therapy;&#xD;
&#xD;
               2. Hepatitis B infection as manifest by the presence of Hepatitis B surface antigen&#xD;
                  (HBsAg);&#xD;
&#xD;
               3. Hepatitis C infection as manifest by positive anti-HCV antibody and positive HCV&#xD;
                  RNA assay at the time of screening;&#xD;
&#xD;
               4. Grade 4 DAIDS laboratory abnormality;&#xD;
&#xD;
               5. Females who are pregnant, lactating, or breastfeeding, or who plan to become&#xD;
                  pregnant during the study;&#xD;
&#xD;
               6. Unexplained fever or clinically significant illness within 1 week prior to the&#xD;
                  first study dose;&#xD;
&#xD;
               7. Any vaccination within 2 weeks prior to the first study dose;&#xD;
&#xD;
               8. Subjects weighing &lt;35kg;&#xD;
&#xD;
               9. History of anaphylaxis to any oral or parenteral drugs;&#xD;
&#xD;
              10. Use of any fusion inhibitors and broadly neutralizing monoclonal antibody prior&#xD;
                  to the Screening Visit;&#xD;
&#xD;
              11. Participation in an experimental drug trial(s) within 30 days of the Screening&#xD;
                  Visit;&#xD;
&#xD;
              12. Any known allergy or antibodies to the study drug or excipients;&#xD;
&#xD;
              13. Treatment with any of the following:&#xD;
&#xD;
                    1. Radiation or cytotoxic chemotherapy with 30 days prior to the screening&#xD;
                       visit;&#xD;
&#xD;
                    2. Immunosuppressants or immunomodulating agents within 60 days prior to the&#xD;
                       screening visit; or&#xD;
&#xD;
                    3. Oral or parenteral corticosteroids within 30 days prior to the Screening&#xD;
                       Visit. Subjects on chronic steroid therapy &gt; 5 mg/day will be excluded with&#xD;
                       the following exception:&#xD;
&#xD;
                         -  Subjects on inhaled, nasal, or topical steroids will not be excluded.&#xD;
&#xD;
              14. Any other clinical condition that, in the Investigator's judgment, would&#xD;
                  potentially compromise study compliance or the ability to evaluate&#xD;
                  safety/efficacy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frontier clinical team</last_name>
    <role>Study Director</role>
    <affiliation>Frontier Biotechnologies Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheng Yao, M.D.</last_name>
    <phone>(+86)025-69648387</phone>
    <email>yaocheng@frontierbiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ABT-3BNC117_201 Investigational Site</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABT-3BNC117_201 Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABT-3BNC117_201 Investigational Site</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABT-3BNC117_201 Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABT-3BNC117_201 Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABT-3BNC117_201 Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABT-3BNC117_201 Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>3BNC117</keyword>
  <keyword>Albuvirtide</keyword>
  <keyword>Broadly neutralizing antibody</keyword>
  <keyword>Long-Acting HIV-1 Fusion Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

